

CLINICAL RESEARCH NEWSLETTER

NOV 2025
VOLUME 1 | ISSUE 8

CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS PENDING ACTIVATION

Research Base	Title	Description
ALLIANCE	A232402CD: PAGODA Randomized Trial of a Proactive Graduated Dose Adjustment Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	- GI cancer patients - Protocol under review - Expected activation: Fall 2025
ECOG-ACRIN	EAQ241CD: FinFit: Addressing Financial Hardship in AYA Cancer Survivors	- Recruiting 408 AYAs - Protocol being prepared at ECOG-ACRIN - Expected start: Winter 2025
Wake Forest	WF2505CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	- Recruiting surgeons who perform abdominopelvic surgery - Expected start: Late Fall 2025 - Limited sites to be opened, reach out to WF ASAP if interested.

Inside this issue

TOPIC	PAGE
Pending CCDR Trials	1
Enrolling CCDR Trials	2
Recently Opened GA NCORP Trials	3
Study Spotlight/Fundamentals Class	4
Upcoming Meetings & Kudos	5
Test Your Knowledge Quiz	6

Contact Information

GA NCORP CCDR Program
Stephanie Reyes, RN, MSN, OCN
(while Alaina Newsome is OOO)
smiths1@sjchs.org

This newsletter was generated by:

CLINICAL RESEARCH NEWSLETTER

NOV 2025
VOLUME 1 | ISSUE 8

ALL OPEN AND ENROLLING CANCER CARE DELIVERY RESEARCH
(CCDR) TRIALS¹

Research Base	Title	CTSU Activation Date
Alliance	A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients	9/26/2025
ECOG-ACRIN	EAQ221CD: Mobile Health for Adherence in Breast Cancer Patients (CONCURxP) <i>Deemed high priority by the Executive Committee.</i>	10/31/2023
	EAQ222CD: Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) <i>Sites must receive approval prior to initiating any study start-up activities.</i>	2/29/2024
SWOG	S2417CD: A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance	8/4/2025
Wake Forest	WF-1805CD: Implementation and Effectiveness Trial of HN-STAR <i>Participant enrollment closed as of 2/13/2025, but practice (non-patient) enrollment is now ongoing.</i>	8/10/2020
	WF-2301CD: Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers ² <i>Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.</i>	7/2/2024
	WF-2303CD: Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practice <i>Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.</i>	7/23/2024

CLINICAL RESEARCH NEWSLETTER

NOV 2025
VOLUME 1 | ISSUE 8

RECENTLY ACTIVATED TREATMENT/INTERVENTIONAL TRIALS¹

Research Base	Title	CTSU Activation Date
Alliance	A032302: Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)	9/26/2025
	A232301CD:AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients	9/23/2025
	A092204: A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer	10/22/2025
	AEWS2431: Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination with Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients with Newly Diagnosed Metastatic Ewing Sarcoma	10/20/2025
NRG	NRG-GY037: A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer	9/29/2025
	NRG-GI012: Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer with Macrovascular Invasion (HELIO-RT)	10/07/2025
ECOG	EA8231: A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer	10/23/2025

CLINICAL RESEARCH NEWSLETTER

NOV 2025
VOLUME 1 | ISSUE 8

STUDY SPOTLIGHT

WF-2502CD

**Surgical Thromboprophylaxis Practices in Oncology Patients
within the NCORP Network (STOP-VTE)
Opening late Fall 2025.**

limited site availability

CORE RESEARCH FUNDAMENTALS TRAINING PROGRAM

CORE Research Fundamentals Training returns
Tentatively January 12-13, 2026, for 2 FULL days of interactive training!
**This 2 day Fundamentals Training class will now be offering
CME credits*!**

Tentatively, we will follow the following schedule**:

Day 1	Day 2
Welcome & Training Overview Georgia NCORP Orientation Oncology 101 Clinical Trials National Clinical Trials Network (NCTN) Clinical Research Roles Regulatory Compliance Interpreting a Protocol Key Clinical Processes to Protect Patient Safety Case Study/Quiz/Questions	Study Lifecycle – ICF, Screening, Eligibility, Enrollment Study Lifecycle – Treatment and Dosing, AE, SAE, UP, Data Entry Protocol Deviations, Violations, and CAPA Plans Site Initiation, Monitoring, and Auditing Assessments, Q&A / Graduation, & Wrap up

Please contact Kaylan Dixon (kdixon@georgiacore.org) and Angelique Brooks (abrooks@georgiacore.org) for additional information and registration details.

We will tentatively have this class to place:

Jan. 12-13, Mar 9-10, May 11-12, Jul 13-14, Sep 14-15
(actual dates subject to change)

*must complete the full class and pass the post test in order to receive CME credits

**Full Agenda will be sent out the first week of December along with sign up link.

CLINICAL RESEARCH NEWSLETTER

NOV 2025
VOLUME 1 | ISSUE 8

UPCOMING RESEARCH BASE MEETINGS*

Research Base	Date	Location
NRG	January 22-24, 2026	San Francisco, CA
SWOG	April 30-May 2, 2026	San Francisco, CA
URCC	September 25-27, 2026	Niagara Falls, NY
Wake Forest	TBD for 2026	Asheville, NC
UPCOMING ROUTINE AUDITS ¹		
ECOG	TBD FOR 2026	Exact dates and method (onsite vs virtual) are pending.
NRG	TBD	
SWOG	TBD for 2027	
URCC	TBD for 2027	
Wake Forest	TBD for 2027	

*Please contact Shantoria Brown (sbrown@georgiacore.org) to discuss travel funds and audit preparation.

KUDOS

Kudos to Julie Thomas, RN, BSN, OCN and Savita Bidyasar, MD the Treating Investigator from Pearlman site GA069 and Ellie Dean, CRC and Tiffany Harkleroad, FNP the Treating Investigator at Liberty County Cancer Care site GA285 for their enrollment efforts on EAQ221CD. Way to go!

Also, Kudos to Stephanie Reyes at LCRP, for being formally invited to serve as the Chair of ECOG-ACRIN's Oncology Nursing Committee. Stephanie has served as a member of the Audit and Pharmacy Committees, as well as co-chair of the Oncology Nursing Committee

GA NCORP CCDR Accruals to date for Year 12

Site	Accrual to date
NHCI	0
LCRP	3
NGMC	0
Navicent	0
JBACC	0
Harbin	0
Pearlman	1
Tift	0
Totals	4

CLINICAL RESEARCH NEWSLETTER

NOV 2025
VOLUME 1 | ISSUE 8

**ELISHA CURRY
AT
NGMC**

**"Test your knowledge"
Quiz Winner October 2025
Will you be this month's winner?**

TEST OF YOUR KNOWLEDGE QUIZ!

The first person to answer correctly will receive Georgia NCORP swag and a shout-out in the next issue! Send your responses to kdixon@georgiacore.org.

1. A site nurse mistakenly performs a PK blood draw 30 minutes outside the allowed window. What's the correct next action?

- A. Discard the sample and pretend it wasn't done.
- B. Report it as a protocol deviation and retain the sample.
- C. Modify the sample time in the EDC to fit the window.
- D. Notify the monitor but take no further action.

2. Before any study-specific procedures are conducted, the participant must provide _____ and _____ on the approved informed consent form.

3. Each staff member performing study procedures must be listed on the _____ and have documentation of _____ prior to performing any study activity.

- A. Delegation of Authority Log; training
- B. 1572; GCP
- C. 1572; Informed Consent
- D. Protocol; Training